SENZIME ABSENZIME ABSENZIME AB

SENZIME AB

No trades
See on Supercharts

SEZI fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

SEZI does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company